Mortality Risk Pricing

Mortality risk pricing is the valuation problem of estimating when an insured person is likely to die so a life insurance policy can be priced as an investment. You bet your life insurance shows why investors in [[ViaticalSettlement|viatical settlements]] and [[LifeSettlement|life settlements]] need this estimate: longer survival means more premiums, a delayed death benefit, and lower annualized returns.

The concept is ethically charged because ordinary human longevity becomes the driver of an investment return. It also creates practical uncertainty: new treatments can make estimates wrong, as happened when late-1990s HIV drugs let many people live far longer than viatical investors expected.

Key Claims

• Life-settlement buyers need medical and actuarial estimates to decide how much to bid.
• Longer survival lowers investor returns through both time delay and additional premium payments.
• A policyholder’s illness history can raise bids because it may shorten expected time to payout.
• Medical progress can damage investor assumptions and change the whole market’s target population.
• Portfolio construction reduces dependence on any single person’s exact death date but does not remove mortality-estimation risk.

Connections

• Life Settlement, Viatical Settlement, and Life Insurance Secondary Market - markets that require mortality estimates.
• Death-Benefit Portfolio - portfolio version of the same risk.
• [[FrankLifeSettlementSeller|Frank]] - seller whose cancer history changes buyer valuation.
• Scott Page - early market builder who sought doctor estimates for investors.
• Investment Risk Management and Portfolio Suitability - broader valuation and risk-control context.